

Jackie J Bosch

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/618478/jackie-j-bosch-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140 papers	18,503 citations	53 h-index	136 g-index
147 ext. papers	21,820 ext. citations	13.4 avg, IF	6 L-index

#	Paper	IF	Citations
140	Functional Abilities of an International Post-Stroke Population: Standard Assessment of Global Everyday Activities (SAGEA) Scale.. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022 , 31, 106329	2.8	1
139	Retention in RCTs of physical rehabilitation for adults with frailty: a systematic review and meta-analysis.. <i>Trials</i> , 2022 , 23, 235	2.8	1
138	Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial.. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022 , 31, 106404	2.8	0
137	Are clinical trials randomising households to lifestyle interventions to delay cognitive decline feasible? A pilot study to determine the beliefs, preferences, and deterrents for households impacted by dementia based on semi-structured interviews.. <i>BMC Geriatrics</i> , 2022 , 22, 322	4.1	
136	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. <i>European Heart Journal</i> , 2021 , 42, 2995-3007	9.5	3
135	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	1
134	Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. <i>Cardiovascular Research</i> , 2021 , 117, 576-584	9.9	10
133	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , 2021 , 117, 942-949	9.9	7
132	Polypill with or without Aspirin in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021 , 384, 216-228	59.2	58
131	The Relationship Between Glucose Control and Cognitive Function in People With Diabetes After a Lacunar Stroke. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e1521-e1528	5.6	4
130	Recognising HIV infection in systems of care for stroke - AuthorsTrepley. <i>Lancet, The</i> , 2021 , 397, 794-795	40	
129	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 14-23	15.1	9
128	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. <i>Stroke</i> , 2021 , 52, 2494-2501	6.7	1
127	Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery: A Post Hoc Analysis From the COMPASS Trial. <i>JAMA Cardiology</i> , 2021 ,	16.2	10
126	Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. <i>Lancet, The</i> , 2021 , 398, 1133-1146	40	16
125	Standardized Assessment of Global activities in the Elderly scale in adult cardiac surgery patients. <i>British Journal of Anaesthesia</i> , 2021 , 127, 539-546	5.4	1
124	Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1934-1944	27.4	95

123	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020 , 141, 1141-1151	16.7	21
122	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. <i>Circulation</i> , 2020 , 141, 1841-1854	16.7	53
121	Oral factor Xa inhibitors and risk of subdural hematoma: COMPASS trial results and meta-analysis. <i>Neurology</i> , 2020 , 95, e480-e487	6.5	1
120	MON-636 The Relationship Between Glucose Control & Cognitive Function in People with Diabetes After a Lacunar Stroke. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
119	ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. <i>Diabetes Care</i> , 2020 , 43, 835-842	14.6	16
118	Are large simple trials for dementia prevention possible?. <i>Age and Ageing</i> , 2020 , 49, 154-160	3	7
117	Feasibility of studying the association between intraoperative regional cerebral oxygen saturation and postoperative functional decline (ReFUNCTION): a pilot sub-study of NeuroVISION-Cardiac Surgery. <i>Canadian Journal of Anaesthesia</i> , 2020 , 67, 1497-1506	3	
116	Stroke systems of care in low-income and middle-income countries: challenges and opportunities. <i>Lancet, The</i> , 2020 , 396, 1443-1451	40	25
115	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. <i>Stroke</i> , 2020 , 51, 2901-2909	6.7	5
114	Promoting Independent Mobility-related Physical ACTivity (IMPACT) in an inpatient stroke rehabilitation unit: a proof-of-concept evaluation of self-management intervention. <i>Disability and Rehabilitation</i> , 2020 , 42, 3172-3181	2.4	2
113	Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. <i>JAMA Neurology</i> , 2020 , 77, 43-48	17.2	25
112	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 296-307	30.9	17
111	Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. <i>European Heart Journal</i> , 2019 , 40, 3771-3778a	9.5	19
110	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019 , 140, 1451-1459	16.7	22
109	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1519-1528	15.1	17
108	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 576-585	7	6
107	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019 , 139, 1134-1145	16.7	72
106	The cost implication of primary prevention in the HOPE 3 trial. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019 , 5, 266-271	4.6	4

105	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , 2019 , 140, 529-537	16.7	50
104	Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INTERvention (ORIGIN) trial. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1502-1505	6.7	1
103	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019 , 14, 270-281	6.3	9
102	Cross-cultural adaptation and psychometric evaluation of the Singapore version of the Chedoke Arm and Hand Activity. <i>Disability and Rehabilitation</i> , 2019 , 41, 2570-2577	2.4	
101	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019 , 157, 682-691.e2	13.3	181
100	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 3271-3280	15.1	56
99	Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019 , 157, 403-412.e5	13.3	62
98	240-LB: Angiotensin-Converting Enzyme and Type 2 Diabetes Risk: A Mendelian Randomization Study. <i>Diabetes</i> , 2019 , 68, 240-LB	0.9	
97	Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. <i>Neurology</i> , 2019 , 92, e1435-e1446	6.5	34
96	Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial. <i>Diabetes Care</i> , 2019 , 42, 142-147	14.6	15
95	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 121-130	15.1	46
94	Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 681-697	3.9	2
93	Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. <i>JAMA Cardiology</i> , 2018 , 3, 225-234	16.2	403
92	Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 38-44	3.8	10
91	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. <i>European Heart Journal</i> , 2018 , 39, 750-757a	9.5	56
90	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2306-2315	15.1	173
89	Comparison of the sensitivity to change of the Functional Independence Measure with the Assessment of Motor and Process Skills within different rehabilitation populations. <i>Disability and Rehabilitation</i> , 2018 , 40, 3177-3184	2.4	12
88	Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	1

87	The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. <i>American Heart Journal</i> , 2018 , 206, 72-79	4.9	12
86	Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 310-315	5.1	2
85	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 205-218	4.0	204
84	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 219-229	4.0	414
83	Reliability and validity of the shortened Singapore versions of the Chedoke Arm and Hand Activity Inventory. <i>International Journal of Rehabilitation Research</i> , 2018 , 41, 297-303	1.8	
82	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1027-1035 ⁹⁷	3.8	97
81	Two phosphAtE taRGETs in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 965-973	6.9	20
80	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1319-1330	59.2	1122
79	Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial. <i>Diabetes Research and Clinical Practice</i> , 2017 , 132, 137-143	7.4	
78	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and ParticipantsTBaseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 311-8	3.8	21
77	Global Survey of the Frequency of Atrial Fibrillation-Associated Stroke: Embolic Stroke of Undetermined Source Global Registry. <i>Stroke</i> , 2016 , 47, 2197-202	6.7	43
76	Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study. <i>Scientific Reports</i> , 2016 , 6, 18672	4.9	50
75	Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1108-16	3.8	6
74	Age disparity in diagnostic evaluation of stroke patients: Embolic Stroke of Undetermined Source Global Registry Project. <i>European Stroke Journal</i> , 2016 , 1, 130-138	5.6	1
73	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2009-20	59.2	382
72	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2021-31	59.2	440
71	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2032-43	59.2	199
70	Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. <i>International Journal of Stroke</i> , 2016 , 11, 526-33	6.3	86

69	Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease. <i>American Journal of Medicine</i> , 2016 , 129, e35-6	2.4	23
68	Does lowering blood pressure with antihypertensive therapy preserve independence in activities of daily living? A systematic review. <i>American Journal of Hypertension</i> , 2015 , 28, 273-9	2.3	8
67	The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 1602-8	6.9	36
66	Development and Evaluation of Self-Management and Task-Oriented Approach to Rehabilitation Training (START) in the Home: Case Report. <i>Physical Therapy</i> , 2015 , 95, 934-43	3.3	8
65	Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin. <i>Evidence-Based Medicine</i> , 2015 , 20, 117		
64	Global survey of the diagnostic evaluation and management of cryptogenic ischemic stroke. <i>International Journal of Stroke</i> , 2015 , 10, 1031-6	6.3	34
63	Obesity genes and risk of major depressive disorder in a multiethnic population: a cross-sectional study. <i>Journal of Clinical Psychiatry</i> , 2015 , 76, e1611-8	4.6	28
62	Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. <i>European Heart Journal</i> , 2014 , 35, 353-64	9.5	57
61	Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. <i>Diabetologia</i> , 2014 , 57, 1325-31	10.3	39
60	The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. <i>Diabetes Care</i> , 2014 , 37, 1360-6	14.6	67
59	Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: a subanalysis of the ORIGIN trial. <i>International Journal of Cardiology</i> , 2014 , 174, 458-61	3.2	64
58	Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 562-72	18.1	37
57	Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. <i>Anesthesiology</i> , 2014 , 120, 564-78	4.3	509
56	The mini-mental state examination, clinical factors, and motor vehicle crash risk. <i>Journal of the American Geriatrics Society</i> , 2014 , 62, 1419-26	5.6	24
55	Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. <i>New England Journal of Medicine</i> , 2014 , 371, 1121-30	59.2	167
54	Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. <i>European Heart Journal</i> , 2014 , 35, 1743-51	9.5	18
53	Does Task-Oriented Practice Improve Upper Extremity Motor Recovery after Stroke? A Systematic Review. <i>ISRN Stroke</i> , 2014 , 2014, 1-10		20
52	Setting the record straight on TIDE: a lost opportunity for patients with diabetes. <i>Diabetologia</i> , 2013 , 56, 1884-7	10.3	1

51	Genetic information and the prediction of incident type 2 diabetes in a high-risk multiethnic population: the EpiDREAM genetic study. <i>Diabetes Care</i> , 2013 , 36, 2836-42	14.6	20
50	Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: a 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis. <i>American Heart Journal</i> , 2013 , 165, 109-15.e3	4.9	22
49	Randomized clinical trials--removing unnecessary obstacles. <i>New England Journal of Medicine</i> , 2013 , 369, 1061-5	59.2	78
48	Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). <i>Diabetes Care</i> , 2013 , 36, 2466-74	14.6	35
47	Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. <i>Diabetologia</i> , 2012 , 55, 36-45	10.3	42
46	Cognitive impairment and risk of cardiovascular events and mortality. <i>European Heart Journal</i> , 2012 , 33, 1777-86	9.5	92
45	n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 309-18	59.2	659
44	Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. <i>European Journal of Preventive Cardiology</i> , 2012 , 19, 755-64	3.9	57
43	Basal insulin and cardiovascular and other outcomes in dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 319-28	59.2	1138
42	Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. <i>Cmaj</i> , 2012 , 184, E329-36	3.5	154
41	Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 2295-304	27.4	579
40	Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. <i>Diabetologia</i> , 2011 , 54, 487-95	10.3	40
39	The fluid study protocol: a randomized controlled study on the effects of bioimpedance analysis and vitamin D on left ventricular mass in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2011 , 31, 529-36	2.8	9
38	Incidence of diabetes following ramipril or rosiglitazone withdrawal. <i>Diabetes Care</i> , 2011 , 34, 1265-9	14.6	28
37	The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. <i>Circulation</i> , 2010 , 122, 2078-88	16.7	120
36	Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes. <i>Diabetologia</i> , 2010 , 53, 1322-30	10.3	21
35	Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). <i>Journal of the American College of Cardiology</i> , 2009 , 53, 2028-35	15.1	50
34	Lipid lowering for primary prevention. <i>Lancet, The</i> , 2009 , 373, 1152-5	40	39

33	Specific barriers to the conduct of randomized trials. <i>Clinical Trials</i> , 2008 , 5, 40-8	2.2	120
32	Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). <i>American Heart Journal</i> , 2008 , 155, 26-32, 32.e1-6	4.9	146
31	Sensible guidelines for the conduct of large randomized trials. <i>Clinical Trials</i> , 2008 , 5, 38-9	2.2	43
30	Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. <i>European Heart Journal</i> , 2007 , 28, 1382-8	9.5	23
29	Effect of ramipril on the incidence of diabetes. <i>New England Journal of Medicine</i> , 2006 , 355, 1551-62	59.2	583
28	Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. <i>Lancet, The</i> , 2006 , 368, 1096-105	4.0	1312
27	The DREAM trial [AuthorsTrepley. <i>Lancet, The</i> , 2006 , 368, 2050-2051	4.0	207
26	Independent design and conduct of clinical trials. <i>Clinical Trials</i> , 2006 , 3, 503-7	2.2	3
25	Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. <i>American Heart Journal</i> , 2005 , 149, 54-60	4.9	252
24	Home and community occupational therapy for children and youth: a before and after study. <i>Canadian Journal of Occupational Therapy</i> , 2005 , 72, 289-97	1.4	17
23	Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 293, 1338-47	27.4	878
22	Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. <i>Circulation</i> , 2005 , 112, 1339-46	16.7	153
21	Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. <i>European Heart Journal</i> , 2004 , 25, 17-24	9.5	218
20	Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. <i>Circulation</i> , 2004 , 110, 1413-7	16.7	46
19	Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. <i>Kidney International</i> , 2004 , 65, 1375-80	9.9	84
18	Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. <i>Diabetologia</i> , 2004 , 47, 1519-27	10.3	139
17	Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 2200-6	15.1	81
16	Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003 , 10, 420-8		32

15	Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , 2003 , 107, 1284-90	16.7	176
14	Preventing stroke with ramipril--authorsTreply. <i>BMJ, The</i> , 2003 , 326, 52	5.9	1
13	Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. <i>Diabetes Care</i> , 2002 , 25, 1919-27	14.6	306
12	Urate levels as a predictor of cardiac deaths: causal relation or mere association?. <i>European Heart Journal</i> , 2002 , 23, 760-1	9.5	11
11	Use of ramipril in preventing stroke: double blind randomised trial. <i>BMJ, The</i> , 2002 , 324, 699-702	5.9	286
10	Effect of long-term therapy with ramipril in high-risk women. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 693-702	15.1	46
9	Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. <i>Annals of Internal Medicine</i> , 2001 , 134, 629-36	8	962
8	Ramipril and the development of diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 1882-5	27.4	390
7	Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. <i>Circulation</i> , 2001 , 104, 1615-21	16.7	439
6	Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. <i>Circulation</i> , 2001 , 104, 522-6	16.7	157
5	Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). <i>Circulation</i> , 2001 , 103, 919-25	16.7	606
4	Vitamin E supplementation and cardiovascular events in high-risk patients. <i>New England Journal of Medicine</i> , 2000 , 342, 154-60	59.2	1573
3	Summary of randomized trials of angiotensin converting enzyme inhibitors. <i>Clinical and Experimental Hypertension</i> , 1999 , 21, 835-45	2.2	16
2	Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. <i>Diabetes Care</i> , 1998 , 19, 1225-8	14.6	55
1	Systematic review: patient-reported outcome measures of fatigue in inflammatory bowel disease. <i>Fatigue: Biomedicine, Health and Behavior</i> , 1-23	2.3	